Alexander Scott - Eisai Director
| ESALYDelisted Stock | USD 13.90 0.21 1.53% |
Director
Mr. Alexander Scott was serving as Executive Officer, Chief Strategy Officer in Neurology Business Group and Director of Strategy in Neurology Business Group in Eisai Co., Ltd. since April 2016. He used to work for another company and a subsidiary, Eisai Inc. since 2016.
| Age | 52 |
| Tenure | 8 years |
| Phone | 81 3 3817 3700 |
| Web | https://www.eisai.co.jp |
Eisai Management Efficiency
Eisai's management efficiency ratios could be used to measure how well Eisai manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 94.89 B in total debt with debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Eisai has a current ratio of 2.02, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Eisai until it has trouble settling it off, either with new capital or with free cash flow. So, Eisai's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eisai sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eisai to invest in growth at high rates of return. When we think about Eisai's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Arthur Einav | Independence Contract Drilling | ||
| Gary Hendrickson | Waters | 64 | |
| Vance Coffman | Amgen Inc | 71 | |
| Sanders Williams | Amgen Inc | 69 | |
| Thomas Salice | Waters | 61 | |
| Wanda Austin | Amgen Inc | 63 | |
| Tighe Noonan | Independence Contract Drilling | 57 | |
| Rebecca Henderson | Amgen Inc | 57 | |
| David Swartz | RadNet Inc | 73 | |
| Joshua Bekenstein | Waters | 56 | |
| Frank Biondi | Amgen Inc | 70 | |
| Lawrence Levitt | RadNet Inc | 74 | |
| Ellen Kullman | Amgen Inc | 62 | |
| Robert Eckert | Amgen Inc | 63 | |
| Fred Hassan | Amgen Inc | 72 | |
| Linda Baddour | Waters | 62 | |
| Norman Hames | RadNet Inc | 68 | |
| Marvin Cadwell | RadNet Inc | 73 | |
| Michael Berendt | Waters | 71 | |
| Greg Garland | Amgen Inc | 56 | |
| William Miller | Waters | 70 | |
Management Performance
| Return On Equity | 0.0386 | |||
| Return On Asset | -0.0069 |
Eisai Leadership Team
Elected by the shareholders, the Eisai's board of directors comprises two types of representatives: Eisai inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eisai. The board's role is to monitor Eisai's management team and ensure that shareholders' interests are well served. Eisai's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eisai's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ryohei Yanagi, Chief Investor Relation Officer, VP and Deputy CFO | ||
| Shinya Watanabe, Director of Accounting in Main Finance & Accounting Unit | ||
| Noboru Naoe, Executive Officer | ||
| Shuzo Kaihori, Independent Director | ||
| Daiken Tsunoda, Independent Director | ||
| Alexander Scott, Executive Officer, Director of Strategy, Chief Strategy Officer of Neurology Business Group | ||
| Yasunobu Kai, Executive Officer and Presidentident of Eisai Japan Oncology hhc Unit, Director of Oncology Medical Division | ||
| Hiroyuki Kato, Executive Officer, Manager of Medicine Development Center | ||
| Yutaka Tsuchiya, Vice President Representative Executive Officer | ||
| Shohei Kanazawa, Executive Officer and Presidentident of Consumer hhc Business Unit | ||
| Osamu Suzuki, Independent Director | ||
| Nobuo Deguchi, Director | ||
| Haruo Naito, CEO, Representative Corporate Officer and Director | ||
| Eiichiro Suhara, Independent Director | ||
| Hideki Hayashi, CIO and Representative Corporate Officer of Corporate Planning and Strategy | ||
| Yasushi Okada, Senior Managing Executive Officer, Chief Talent Officer, Chief Director of Human Resources Development, Director of Talent Management | ||
| Hajime Shimizu, CFO and Representative Corporate Officer | ||
| Yasuhiko Kato, Independent Director | ||
| Hideshi Honda, Senior Managing Executive Officer, Representative Executive Officer and Presidentident of Asia Region | ||
| Junichi Asatani, Chief Compliance Officer, Executive Officer | ||
| Kenji Matsumae, Executive Officer and Presidentident of Eisai Japan and Presidentident of Integrated Community hhc Unit | ||
| Shaji Procida, VP and President of Eisai Inc and COO of Eisai Inc | ||
| Mitsuaki Tanaka, Executive Officer, Chief Strategy Officer | ||
| Tamaki Kakizaki, Independent Director | ||
| Hiroyuki Kobayashi, Executive Officer, Chief Medical Officer of Japan & Asia, Chief Director of Medical, Director of Neurology Medical Department | ||
| Kazumasa Nagayama, Executive Officer, Chief Strategy Officer, Director of Corporate Strategy | ||
| Kiyochika Ohta, Independent Director | ||
| Masatomi Akana, Executive Officer | ||
| Gary Hendler, Sr. VP, CEO of Eisai Europe Ltd and President of Eisai Europe Ltd and President of EMEA Region and President of Eisai Global Oncology Bus. Unit | ||
| Yoshiteru Kato, Executive Officer and Presidentident of Eisai Demand Chain Systems | ||
| Edward Geary, Managing Executive Officer, Chief Medical Officer, Chief Director of Corporate Medical Affairs, Chairman of Global Safety Board | ||
| Yuji Matsue, Executive Officer, Deputy President of Asia Region | ||
| Tatsuyuki Yasuno, Executive Officer, Director of Corporate Planning & Strategy | ||
| Hidenori Yabune, Executive Officer, Director of Integrated Marketing in Eisai Japan | ||
| Frank Ciriello, VP and President of Eisai Global Neurology Bus. Unit | ||
| Sayoko Sasaki, Executive Officer, Director of PR, Manager of Global Access Strategies Office | ||
| MD FAAN, VP Health | ||
| Yanhui Feng, Executive Officer, General Manager of Subsidiaries | ||
| Kenta Takahashi, Sr. VP, Executive Director of Legal Department and General Counsel of Intellectual Property | ||
| Ryuichi Murata, Independent Director | ||
| Takashi Ohwa, Executive Officer, Chief Innovation Officer of Eisai Product Creation Systems | ||
| Hideyo Uchiyama, Independent Director | ||
| Lynn Kramer, VP and President of Neuroscience and General Medicine Pcu for Eisai Product Creation Systems, Chief Clinical Officer of Eisai Product Creation Systems and Chief Medical Officer of Eisai Global Neurology Bus. Unit | ||
| Ikuo Nishikawa, Independent Director | ||
| Teruyuki Masaka, VP Officer | ||
| Graham Fry, Independent Director | ||
| Teiji Kimura, Executive Officer, Director of Global Discovery Research, Deputy President of Neuroscience & General Medicine PCU Unit | ||
| Akiko Nakahama, Executive Officer, Manager of Medicine Development Center | ||
| Ivan Cheung, Executive Officer, Senior Director of Corporate Business | ||
| Patricia Robinson, Independent Director | ||
| Rami Suzuki, Executive Officer, Director of Corporate BD | ||
| Hirokazu Kanai, Director of Accounting | ||
| Yosuke Akita, Chief VP | ||
| Terushige Iike, Executive Officer and Presidentident of Japan/Asia Clinical Research PCU for Eisai Product Creation Systems, Director of Clinical Development | ||
| Satoru Yasuda, Executive Officer and Presidentident of Integrated Community hhc Unit in Eisai Japan | ||
| Nadeem Sarwar, President | ||
| Hideaki Matsui, Director | ||
| Bruce Aronson, Independent Director | ||
| Takashi Owa, Executive Officer, Chief Innovation Officer | ||
| Takafumi Asano, Senior Managing Executive Officer and Presidentident of Eisai Demand Chain Systems | ||
| Tokuji Izumi, Independent Director | ||
| Toru Yamashita, Independent Director | ||
| Masayuki Miyajima, Executive Officer and Presidentident of Subsidiary |
Eisai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eisai a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0386 | |||
| Return On Asset | -0.0069 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 18.8 B | |||
| Shares Outstanding | 286.7 M | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 22.74 X | |||
| Price To Book | 3.37 X | |||
| Price To Sales | 0.03 X |
Pair Trading with Eisai
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eisai position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eisai will appreciate offsetting losses from the drop in the long position's value.Moving against Eisai Pink Sheet
| 0.87 | GE | GE Aerospace Earnings Call This Week | PairCorr |
| 0.85 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.84 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
| 0.84 | JPM | JPMorgan Chase Financial Report 12th of July 2024 | PairCorr |
| 0.83 | CE | Celanese Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Eisai could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eisai when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eisai - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eisai Co to buy it.
The correlation of Eisai is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eisai moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eisai moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eisai can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Eisai Pink Sheet
If you are still planning to invest in Eisai check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eisai's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |